🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07299877
Starting soon Phase 4

Perineural Dexamethasone, Dexmedetomidine, or Their Combination to Reduces Rebound Pain After Supraclavicular Brachial Plexus Block

NCT07299877 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 4
Started
2025-12-28
Last updated
2026-01-09

Condition(s) studied

Brachial Plexus Blocks

Investigational drug(s) / intervention(s)

Group A (Dexamethasone)Group B (Dexmedetomidine)Group C (Dexamethasone + Dexmedetomidine)All Dexamethasone trials (325) →All Dexmedetomidine trials (144) →

Group A (Dexamethasone): 8 mg of dexamethasone will be added to the local anesthetic. The local anesthetic used in all cases was a mixture of 10 ml of 2% xylocaine and 10 ml of 0.5% bupivacaine.

Group B (Dexmedetomidine): 1 microgram/kg of dexmedetomidine will be added to the local anesthetic. The local anesthetic used in all cases was a mixture of 10 ml of 2% xylocaine and 10 ml of 0.5% bupivacaine.

Group C (Dexamethasone + Dexmedetomidine): 8 mg of dexamethasone + 1 microgram/kg dexmedetomidine will be added to the local anesthetic. The local anesthetic used in all cases was a mixture of 10 ml of 2% xylocaine and 10 ml of 0.5% bupivacaine.

Study summary

Dexmedetomidine, an α2 adrenoceptor agonist, and dexamethasone, a potent anti-inflammatory steroid, are commonly used, effective, and safe adjuvants to peripheral nerve block (PNB). Both have been found to delay and reduce the incidence of rebound pain (RP), prolong the duration of sensory and motor block, and enhance analgesia without causing significant respiratory depression. Few studies have explored the effectiveness of dexmedetomidine or dexamethasone as sole adjuvants to PNB for preventing or reducing RP. However, no study has directly compared the effectiveness of these two drugs in reducing RP when used as adjuvants to local anesthetic (LA) in PNB. Due to differences in their mechanism of action, their effects on RP may differ significantly. The investigators hypothesized that the combination of dexamethasone and dexmedetomidine reduces the incidence of RP when used as adjuvants to LA in PNB.

Eligibility

Sex
ALL
Min age
20 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * from 20-65 years old * and ASA physical status I or II and III, * and of either gender, * who provided informed, written, and valid consent, * were scheduled for elective orthopedic upper limb surgeries for traumatic fractures under Supraclavicular Brachial Plexus Block. Exclusion Criteria: * Patients with coagulopathies, * neurological disorders, * hypersensitivity to any of the study drugs, or * a history of previous surgeries on the affected limb * and those who refused to sign informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Benha University, Faculty of Medicine Banhā Qalyubiyya

More Al-Azhar University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07299877 on ClinicalTrials.gov ↗ ← All trials in Egypt